• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

    1/8/25 7:00:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email

    Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance 

    Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2

    Announces New $250 million Accelerated Share Repurchase

    Conference Call Scheduled Today at 5:30am PT/8:30am ET

    SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance. The Company also announced it has recently entered into a new $250 million accelerated share repurchase (ASR) program under its previously announced $750 million share repurchase program.

    "Halozyme is at the forefront of drug delivery innovation, fostering a high-growth and durable business underpinned by our proprietary ENHANZE drug delivery technology. This leadership position is reflected in the global launch of nine ENHANZE co-formulated products, a robust pipeline and continuing interest from potential new partners," said Dr. Helen Torley, president and chief executive officer. "Our 2025 guidance, with projected revenue growth of 16% to 23% and adjusted EBITDA growth of 24% to 32%, is largely driven by VYVGART Hytrulo, which has received strong early acceptance in generalized myasthenia gravis, and is now seeing growing adoption in CIDP following the June 2024 U.S. approval, and by the continued strong growth of Darzalex SC and Phesgo. Three additional products, Ocrevus Zunovo, Tecentriq Hybreza and Opdivo Qvantig, which are in the early stages of commercialization following recent approvals, are projected to contribute modestly in 2025, growing meaningfully from 2026 onwards. The combined continued projected growth of each product in this exciting de-risked portfolio is what resulted in our also raising our multi-year guidance."

    Table 1. 2024 Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2024



    2024 Estimate

    Total Revenue

    $970 to $1,020 million

    Royalty Revenue

    $550 to $565 million

    Net Income

    $419 to $443 million

    Adjusted EBITDA

    $595 to $625 million

    GAAP Diluted EPS

    $3.22 to $3.40

    Non-GAAP Diluted EPS

    $4.00 to $4.20



    Footnotes:

    1

    Growth rates calculated from 2024 midpoint to low end of 2025 range and high-end of 2025 range. See "2025 Financial Guidance" below.

    2

    Adjusted EBITDA and non-GAAP Diluted EPS are non-GAAP financial measures. See "Note Regarding Use of Non-GAAP Financial Measures" below for an explanation of these measures.

    Financial Outlook for 2025

    The Company is raising its financial guidance for 2025. For the full year 2025, the Company expects:

    • Total revenue of $1,150 million to $1,225 million, representing growth of 16% to 23% over projected 2024 total revenue, primarily driven by increases in royalty revenue and product sales from XYOSTED®.



    • Revenue from royalties of $725 million to $750 million, representing growth of 30% to 35% over 2024.



    • Adjusted EBITDA of $755 million to $805 million, representing growth of 24% to 32% over 2024.



    • Non-GAAP diluted earnings per share of $4.95 to $5.35, representing growth of 21% to 30% over 2024. The Company's earnings per share guidance does not consider the impact of potential future share repurchases.

    Table 2. 2025 Financial Guidance





    Previous Guidance

    Range



    New Guidance Range

    Expected

    YoY Growth1

    Total Revenue



    $1,095 to $1,170 million



    $1,150 to $1,225 million

    16% to 23%

    Royalty Revenue



    $650 to $675 million



    $725 to $750 million

    30% to 35%

    Adjusted EBITDA



    $710 to $760 million



    $755 to $805 million

    24% to 32%

    Non-GAAP Diluted EPS



    $4.45 to $4.85



    $4.95 to $5.35

    21% to 30%





    Footnote:

    1

    Growth rates calculated from 2024 midpoint to low end of 2025 range and high-end of 2025 range.

    Website and Conference Call

    Halozyme will host an Investor Conference Call today, Wednesday, January 8 at 5:30am PT/8:30am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I871904593. A webcast of the live call and presentation materials (which will be available 15 minutes before the start of the call) will be available through the "Investors" section of Halozyme's corporate website at ir.halozyme.com.

    About Halozyme

    Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

    Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

    Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

    For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

    Note Regarding 2024 Preliminary Results

    The financial results presented herein are preliminary, estimated, and unaudited. They are subject to the completion and finalization of the Company's financial and accounting close procedures. They reflect management's estimates based solely upon information available to management as of the date of this press release. Further information learned during the completion and finalization of these procedures may alter the final results. These preliminary estimates should not be considered a substitute for the financial information to be filed with the Securities and Exchange Commission on the Company's Form 10-K for the year ended December 31, 2024 once it becomes available. There is a possibility that the Company's financial results for the twelve months ended December 31, 2024 could vary materially from these preliminary estimates. Accordingly, you should not place undue reliance upon this preliminary information.

    Note Regarding Use of Non-GAAP Financial Measures

    In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release and the accompanying tables contain certain non-GAAP financial measures. The Company reports earnings before interest, taxes, depreciation, and amortization ("EBITDA"), adjusted EBITDA, Non-GAAP diluted earnings per share and non-GAAP diluted shares and guidance with respect to those measures, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time changes, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, and certain adjustments to income tax expense. The Company calculates non-GAAP diluted shares excluding the dilutive impact of convertible notes which is used in calculating non-GAAP diluted earnings. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding one-time items, if any such as changes in contingent liabilities, inventory adjustments and impairment charges. Reconciliations between GAAP and Non-GAAP financial measures are included at the end of this press release. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in share-based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the U.S. GAAP measures may be materially different than the non-GAAP measures.

    The Company evaluates other items of income and expense on an individual basis for potential inclusion in the calculation of Non-GAAP financial measures and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company's ongoing business operations and (iii) whether or not the Company expects it to occur as part of the Company's normal business on a regular basis. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similarly titled measures presented by other companies. These non-GAAP financial measures are not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures, and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures.

    The Company considers these non-GAAP financial measures to be important because they provide useful measures of the operating performance of the Company, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The non-GAAP measures also allow investors and analysts to make additional comparisons of the operating activities of the Company's core business over time and with respect to other companies, as well as assessing trends and future expectations. The Company uses non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs.

    Safe Harbor Statement

    In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's financial performance (including preliminary results for the fiscal year ended December 31, 2024 and the Company's expected financial outlook for 2025) and expectations for future growth, profitability, total revenue, royalty revenue, EBITDA, Adjusted EBITDA, and non-GAAP diluted earnings-per-share. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery. Forward-looking statements regarding the Company's business may include potential growth and receipt of royalty and milestone payments driven by our partners' development and commercialization efforts, potential new clinical trial study starts and clinical data, regulatory submissions and product launches, the size and growth prospects of our partners' drug franchises, potential new or expanded collaborations and collaborative targets and regulatory review, and potential approvals of new partnered or proprietary products, and the potential timing of these events. These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "preliminary," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, unexpected results or delays in the growth of the Company's business, or in the development, regulatory review or commercialization of the Company's partnered or proprietary products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release.

    Contacts: 

    Tram Bui

    VP, Investor Relations and Corporate Communications

    609-359-3016

    [email protected]

    Samantha Gaspar

    Teneo

    212-886-9356

    [email protected] 

    The following tables reconcile, for the twelve months ended December 31, 2024, the Company's estimated ranges of 2024 EBITDA and 2024 Adjusted EBITDA to the Company's estimated ranges of 2024 Net Income, and 2024 Non-GAAP Diluted EPS to the Company's estimated ranges of 2024 GAAP Diluted EPS.

     

    Halozyme Therapeutics, Inc. 

    GAAP to Non-GAAP Reconciliations

    Preliminary Net Income and Diluted EPS

    (Unaudited)

    (In millions, except per share amounts)







    Twelve Months Ended

    December 31, 2024

    GAAP Net Income



    $     419  -  443

    Adjustments





    Investment and other income



    (23)  -  (23)

    Interest expense



    18  -  18

    Income tax



    100  -  105

    Depreciation and amortization



    82  -  82

    EBITDA



    595  -  625

    Adjustments



    —

    Adjusted EBITDA



    $     595  -  625







    GAAP Diluted EPS



    $   3.22  -  3.40

    Adjustments





    Share-based compensation



    0.32  -  0.35

    Amortization of debt discount



    0.06  -  0.06

    Amortization of intangible assets



    0.55  -  0.55

    Income tax effect of above adjustments(1)



    (0.15)  -  (0.16)

    Non-GAAP Diluted EPS



    $    4.00  -  4.20







    GAAP Diluted Shares



    129.8  -  130.4

    Adjustments





    Adjustment for dilutive impact of senior 2028 Convertible Notes(2)



    (0.4)  -  (0.4)

    Non-GAAP Diluted Shares



    129.4  -  130.0



    Note:  Dollar amounts, as presented, are rounded. Consequently, totals may not add up.





    (1)

    Adjustments relate to taxes for the reconciling items, as well as excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items.

    (2)

    Adjustment made for the dilutive effect of our Convertible Senior Notes due 2028 when the effect is not the same on a GAAP and non-GAAP basis for the reporting period.

     

    Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-reiterates-2024-financial-guidance-and-raises-2025-and-multi-year-financial-guidance-302345137.html

    SOURCE Halozyme Therapeutics, Inc.

    Get the next $HALO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    2/29/2024$54.00Outperform
    TD Cowen
    7/24/2023$61.00Buy
    H.C. Wainwright
    7/24/2023$43.00 → $45.00Buy → Neutral
    Goldman
    More analyst ratings

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      11/12/24 9:36:57 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Halozyme Therapeutics Inc.

      SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      10/17/24 9:36:19 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      2/13/24 5:06:13 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Halozyme Therapeutics Inc.

      SCHEDULE 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      5/13/25 11:18:25 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Halozyme Therapeutics Inc.

      10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:08:30 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:06:31 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Posard Matthew L. was granted 4,165 shares, increasing direct ownership by 6% to 74,039 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:11:14 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miyashita Akiko Moni was granted 4,165 shares, increasing direct ownership by 20% to 24,937 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:09:44 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:08:05 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • Mahesh Krishnan Elected to Halozyme's Board of Directors

      SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

      4/25/24 4:45:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Appoints Barbara Duncan to its Board of Directors

      SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan

      2/6/23 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Financials

    Live finance-specific insights

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

      Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance  Reiterating 2025 Finan

      2/18/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

      SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the

      5/5/25 5:15:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equal-Weight and set a new price target of $62.00

      5/14/25 8:56:30 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and set a new price target of $47.00

      5/13/25 8:55:01 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously

      10/7/24 8:32:56 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care